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The entry into mitosis is controlled by Cdc2/cyclin B,
also known as maturation or M-phase promoting factor
(MPF). In Xenopus egg extracts, the inhibitory phospho-
rylations of Cdc2 on Tyr-15 and Thr-14 are controlled by
the phosphatase Cdc25 and the kinases Myt1 and Wee1.
At mitosis, Cdc25 is activated and Myt1 and Wee1 are
inactivated through phosphorylation by multiple ki-
nases, including Cdc2 itself. The Cdc2-associated Suc1/
Cks1 protein (p9) is also essential for entry of egg ex-
tracts into mitosis, but the molecular basis of this
requirement has been unknown. We find that p9
strongly stimulates the regulatory phosphorylations of
Cdc25, Myt1, and Wee1 that are carried out by the Cdc2/
cyclin B complex. Overexpression of the prolyl isomer-
ase Pin1, which binds to the hyperphosphorylated forms
of Cdc25, Myt1, and Wee1 found at M-phase, is known to
block the initiation of mitosis in egg extracts. We have
observed that Pin1 specifically antagonizes the stimula-
tory effect of p9 on phosphorylation of Cdc25 by Cdc2/
cyclin B. This observation could explain why overex-
pression of Pin1 inhibits mitotic initiation. These
findings suggest that p9 promotes the entry into mitosis
by facilitating phosphorylation of the key upstream reg-
ulators of Cdc2.
The entry into mitosis in eukaryotic cells is controlled by
maturation or M-phase promoting factor (MPF)1 (1). In Xeno-
pus egg extracts, MPF is a trimeric complex consisting of the
protein kinase Cdc2, a B-type cyclin, and a small 9-kDa subunit
called Xe-p9 (p9), a homolog of the Suc1/Cks protein (2). MPF
acts by carrying out key regulatory phosphorylations on vari-
ous substrates that are involved in mitotic processes such as
nuclear disassembly and chromosome transmission. In addi-
tion, MPF participates in regulatory circuits that control its
“autocatalytic” activation at the G2/M transition (3, 4) and its
inactivation at the conclusion of M-phase, respectively (1).
During interphase, Cdc2 is kept inactive because of inhibi-
tory phosphorylations on its Tyr-15 and Thr-14 residues. These
modifications are catalyzed by the kinases Wee1 and Myt1 (1).
The dual-specificity phosphatase Cdc25 removes both inhibi-
tory phosphates when the conditions are appropriate for mito-
sis, thereby activating Cdc2 (1). Cdc25, Myt1, and Wee1 are all
highly regulated during the cell cycle (5–10). For example,
these enzymes become highly phosphorylated at mitosis and
concomitantly undergo large changes in their catalytic activi-
ties. In particular, the kinases Cdc2/cyclin B and Plx1 collabo-
rate to carry out the stimulatory phosphorylations of Cdc25
(3–5, 11). Conversely, the Cdc2-specific kinase activities of both
Myt1 and Wee1 are strongly down-regulated by phosphoryla-
tion at mitosis (7–10).
The Suc1/Cks protein is also essential for the proper regula-
tion of Cdc2 in various species (2, 12–15). In Xenopus egg
extracts, p9 is required for both entry into and exit from mitosis
(2). The role of p9 in mitotic exit is now understood in some
detail. In particular, p9 is necessary for the destruction of
cyclin B and the phosphorylation of various proteins associated
with ubiquitin-mediated proteolysis (e.g. Cdc27 and BIME)
(16). In the case of Cdc27, p9 was shown to strongly enhance
the ability of Cdc2/cyclin B to phosphorylate recombinant
Cdc27 without affecting the intrinsic catalytic activity of Cdc2,
indicating that p9 facilitates substrate recognition (16, 17).
Significantly, immunodepletion of p9 also prevents the entry of
Xenopus interphase egg extracts into M-phase, but the molec-
ular basis of this defect has not been resolved. In the absence of
p9, the Cdc2/cyclin B complex accumulates in its inactive form
that is phosphorylated on Tyr-15 and Thr-14, suggesting that
p9 in some manner regulates the dephosphorylation of these
residues.
The Pin1 protein has recently emerged as another potential
regulator of mitotic progression (18–22). The human Pin1 pro-
tein was identified in a yeast two-hybrid assay by virtue of its
ability to interact with the mitotic regulatory kinase NIMA
(18). Pin1 is a nuclear protein that has two structural domains:
an N-terminal WW domain that is involved in protein-protein
interactions and a C-terminal prolyl-isomerase domain. Deple-
tion of Pin1 from HeLa cells results in a mitotic arrest, whereas
overexpression of Pin1 in HeLa cells causes a G2 arrest (18).
Similarly, the addition of excess recombinant human His6-Pin1
protein to cycling Xenopus egg extracts can block the entry of
these extracts into mitosis (20, 21). These studies indicated
that Pin1 can impinge upon the Cdc2/cyclin B-dependent path-
way of mitotic regulation.
In this report, we have examined the requirement for p9 in
regulating the G2/M transition. We find that p9 significantly
stimulates the ability of a Cdc2/cyclin B complex to phospho-
rylate the mitotic regulators Cdc25, Myt1, and Wee1. This
observation suggests that p9 plays an indispensable role in the
“autocatalytic” activation of MPF at the G2/M transition. In the
course of these studies, we also observed that excess Pin1
protein can antagonize the stimulatory effect of p9 on the
phosphorylation of the regulators of Cdc2, suggesting that Pin1
may likewise participate in the activation of Cdc2.
EXPERIMENTAL PROCEDURES
Analysis of Xenopus Cdc25, Myt1, and Wee1 Proteins—His6-Cdc25
and His6-Myt1 proteins were purified from baculovirus-infected Sf9
cells as described (10, 11). Phosphorylation of these proteins was ana-
lyzed using 8% SDS gel electrophoresis. 35S-Labeled Xenopus Wee1 was
synthesized using pET3a-XeWee1 as the template (7) and the TNT in
vitro transcription/translation system (Promega Corp.) in the presence
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of [35S]Translabel (ICN Biomedicals, Inc., Irvine, CA). Analysis of the
phosphorylation products was performed by SDS-gel electrophoresis
with a 10% polyacrylamide gel containing 0.357% piperazine diacryl-
amide (Bio-Rad) instead of 0.267% bisacrylamide.
Production of Recombinant Pin1 Proteins—Wild-type His6-Pin1 was
expressed and purified from Escherichia coli BL21(DE3)pLysS cells
using the pET28a-His6-Pin1 construct (18) as described (19) except that
the protein was induced at an optical density of 0.5 (600 nm). A plasmid
encoding the mutant His6-Pin1-W34A protein was constructed with the
QuikChangeTM Site-directed Mutagenesis kit (Stratagene), using
pET28a-His6-Pin1 as the template (18) and two oligonucleotides with
the following sequences: 59-CACATCACTAACGCTAGCCAGGCGGAG-
CGGCCCAGCG-39 and 59-CGCTGGGCCGCTCCGCCTGGCTAGCGT-
TAGTGATGTG-39. This procedure resulted in the conversion of the
Trp-34 to Ala (100TGG103 to 100GCG103) as well as the insertion of a
silent mutation in the coding region of His6-Pin1 (91GCC93 to 91GCT93)
that allowed for the identification of the mutant clone by restriction
analysis with NheI and EcoRV. These mutations were further con-
firmed by sequencing. The mutant His6-Pin1-W34A protein was then
expressed and purified as described above for the wild-type protein.
RESULTS AND DISCUSSION
To assess the role that p9 plays in mitotic entry, we exam-
ined whether p9 would affect the Cdc2-dependent phosphoryl-
ation of various regulators of the G2/M transition. For this
purpose, we incubated recombinant Xenopus Cdc25, Myt1, and
Wee1 with a dimeric Cdc2/Dcyclin B complex or trimeric p9/
Cdc2/Dcyclin B complex. For Cdc25 and Myt1, phosphorylation
was assessed by monitoring 32P incorporation and mobility
during gel electrophoresis. As shown in Fig. 1 (top and middle
panels), p9 strongly stimulated the incorporation of radioactive
phosphate into both His6-Cdc25 and His6-Myt1. Furthermore,
treatment with p9/Cdc2/Dcyclin B, but not Cdc2/Dcyclin B,
resulted in a large decrease in the electrophoretic mobilities of
both Cdc25 and Myt1, which is characteristic of the mitotic
forms of these proteins. The presence of p9 in the Cdc2/Dcyclin
B complex consistently resulted in a 4- to 5-fold increase in the
appearance of the hyperphosphorylated forms of Cdc25 and
Myt1. Because Xenopus Wee1 possesses substantial autophos-
phorylation activity and undergoes less extensive modification
at mitosis, we assessed its phosphorylation by monitoring the
shifting of 35S-Wee1 in SDS gels under modified electrophoretic
conditions (see “Experimental Procedures”). We observed that
p9 also significantly increased the phosphorylation of 35S-Wee1
by Cdc2/Dcyclin B, but to a lesser degree than for Cdc25 and
Myt1 (Fig. 1, bottom panel).
The prolyl isomerase Pin1 binds to the phosphorylated forms
of Cdc25, Myt1, and Wee1, as well as other mitotic phospho-
proteins near the beginning of M-phase (18–22). Overexpres-
sion of Pin1 in human cells (18) and Xenopus egg extracts
inhibits the entry into mitosis (20, 21). Depletion of Pin1 from
human cells by expression of an antisense construct and dele-
tion of the gene encoding the budding yeast Pin1 homologue
Ess1 both result in a defect in the progression through mitosis
(18). Although the precise physiological role of Pin1 has not
been established, these data collectively suggest that Pin1, like
p9, plays some role both in the entry into and progression
through mitosis.
We asked whether Pin1 might affect the ability of p9 to
stimulate substrate recognition by Cdc2/Dcyclin B. Recombi-
nant His6-Pin1 (100 mg/ml) completely abolished the stimula-
tory effect of p9 on the Cdc2-catalyzed phosphorylation of His6-
Cdc25 and His6-Myt1 (Fig. 2A). In dose-response studies with
His6-Cdc25 as the substrate, we observed that half-maximal
inhibition of the p9-stimulated phosphorylation of Cdc25 oc-
curred at ;50 mg/ml His6-Pin1 (Fig. 2B). Previously, the en-
dogenous concentration of Pin1 in Xenopus egg extracts was
estimated to be 0.5 mM or 9 mg/ml (20). Furthermore, recombi-
nant Pin1 at a final concentration of 10 mM (180 mg/ml) com-
pletely blocked the entry of egg extracts into mitosis (20). Thus,
the concentration of His6-Pin1 that inhibits the p9-dependent
phosphorylation of Cdc25 by Cdc2/Dcyclin B is within the range
previously established to block mitosis in egg extracts.
In control experiments, we examined whether His6-Pin1
would affect the catalytic activity of p9/Cdc2/Dcyclin B toward
the generic substrate histone H1. As shown in Fig. 2C, up to
100 mg/ml His6-Pin1 had no effect on the ability of p9/Cdc2/
Dcyclin B to phosphorylate histone H1. As reported previously
(16), Cdc2/Dcyclin B and p9/Cdc2/Dcyclin B phosphorylated
histone H1 with equal efficiency (Fig. 2C, compare lanes a and
b). The Cdc25 protein can also be phosphorylated and regulated
by the Polo-like kinases (Plx1 in Xenopus) (11). However, His6-
Pin1 (100 mg/ml) had no inhibitory effect on the ability of Plx1
to phosphorylate Cdc25 in vitro (data not shown). Finally, we
examined the possibility that His6-Pin1 might disrupt the
binding of p9 to Cdc2/Dcyclin B because p9 does possess a
proline-containing region that has been implicated in control-
ling the binding of Suc1/Cks proteins to cyclin-dependent ki-
nases (23–25). By immunoblotting with anti-p9 antibodies (2),
we observed that His6-Pin1 (100 mg/ml) did not affect the
binding of p9 to Cdc2/Dcyclin B (data not shown).
Pin1 consists of a carboxyl-terminal prolyl isomerase domain
and an amino-terminal WW domain that binds to peptides
containing phosphoserine or phosphothreonine (22). Its WW
domain is critical for the association of Pin1 with mitotic phos-
phoproteins such as Cdc25. To ask whether the WW domain of
Pin1 is necessary for its ability to antagonize p9, we prepared
the mutant His6-Pin1-W34A in which the function of the WW
domain was abolished by mutagenesis of Trp-34 to Ala. As
shown in Fig. 3, the mutant His6-Pin1-W34A, in contrast to
wild-type His6-Pin1, was not able to inhibit the p9-stimulated
hyperphosphorylation of Cdc25. In contrast, a form of Pin1
with a mutation in the prolyl isomerase domain (Pin1-H59A)
(19–20) could still inhibit the stimulatory effect of p9 on the
phosphorylation of Cdc25 (data not shown). Thus, the WW
FIG. 1. p9 strongly enhances phosphorylation of the mitotic
regulators Cdc25, Myt1, and Wee1 by Cdc2/cyclin B. Recombinant
His6-Cdc25 (top panel), His6-Myt1 (middle panel), and 35S-Wee1 (bot-
tom panel) were incubated in 30 ml of kinase buffer (5 mM Tris-HCl at
pH 7.5, 10 mM MgCl2, 1 mM dithiothreitol, 0.1 mg/ml ovalbumin, 1 mM
okadaic acid, and 100 mM ATP) without a Cdk complex (lane a), with
Cdc2/Dcyclin B (lane b), or with p9/Cdc2/Dcyclin B (lane c). Recombinant
Cdc2/Dcyclin B and p9/Cdc2/Dcyclin B were prepared as described (16)
and used at a final concentration of ;50 nM (Dcyclin B is a histidine-
tagged form of the human cyclin B1 protein lacking the N-terminal 87
amino acids which contain the cyclin destruction box). Reactions with
His6-Cdc25 and His6-Myt1 also contained 5 mCi [g-32P]ATP. His6-
Cdc25 and His6-Myt1 were used at a final concentration of ;300 nM. All
kinase reactions were incubated at 22 °C for 15 min and then subjected
to SDS-polyacrylamide gel electrophoresis and analyzed with a Phos-
phorImager (Molecular Dynamics). All experiments were performed a
minimum of three times.
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domain of Pin1 is crucial for its ability to impair the phospho-
rylation of Cdc25.
In summary, one finding of this report is that p9 strongly
enhances the ability of Cdc2 to phosphorylate its key upstream
regulators (e.g. Cdc25, Myt1, and Wee1) (Fig. 4). Mitotic hyper-
phosphorylation results in up-regulation of Cdc25 (3–6) and
down-regulation of Wee1 (7–9) and Myt1 (10), respectively.
Cdc2/cyclin B appears to play a crucial role in these mitotic
hyperphosphorylations. Although Plx1 and possibly other ki-
nases participate in this process, it is not fully clear whether
Plx1 acts upstream or downstream of Cdc2. Taken together,
our results strongly suggest that the arrest of p9-depleted
Xenopus egg extracts in interphase can be attributed at least in
part to a failure in the Cdc2-dependent hyperphosphorylation
of Cdc25, Myt1, and Wee1. Consequently, Cdc25 could not be
activated and both Myt1 and Wee1 could not be inactivated in
the absence of p9. Thus, p9 should be regarded as an essential
component of MPF. Conceivably, p9 could play an additional
role(s) in regulating the G2/M transition, such as affecting the
ability of Cdc25, Myt1, and Wee1 to modify Cdc2, but we have
not been able to detect any effect of p9 on the catalytic functions
of Cdc25, Myt1, and Wee1 (data not shown).
In structural studies, the Suc1/Cks protein has been shown
to contain a potential phosphate-binding pocket (25). In prin-
ciple, this pocket could allow p9 to dock onto phosphoproteins
such as Cdc25, Myt1, and Wee1. In this event, p9 could stim-
ulate the further phosphorylation of these proteins by Cdc2/
cyclin B through its ability to increase the local concentration of
Cdc2 in relation to its substrates. The action of p9 as a sub-
strate-docking factor could help to explain the kinetics of mi-
totic entry in Xenopus egg extracts. In this system, the activa-
tion of Cdc2 by cyclin B requires a critical threshold
concentration of cyclin B and involves a substantial lag period
between the binding of cyclin B to Cdc2 and the ensuing acti-
vation of this complex (26).
Another conclusion of this study is that Pin1 can disrupt the
stimulatory action of p9 through the ability of its WW domain
to bind to the same regulators (e.g. Cdc25, Myt1, and Wee1)
that are also substrates of p9/Cdc2/cyclin B (Fig. 4). The ability
of Pin1 to block the activation of Cdc25 and inactivation of
Wee1 and Myt1 could explain why overexpression of Pin1
blocks the entry into mitosis in Xenopus egg extracts and hu-
man cells. There are conflicting reports about whether Pin1 can
directly inhibit the phosphatase activity of Cdc25 (20, 21), but
we have not been able to observe an inhibitory effect of human
Pin1 on the catalytic activity of Xenopus Cdc25 (data not
shown). Thus, although Pin1 may be able to inhibit the cata-
lytic function of Cdc25 under certain assay conditions, we sug-
gest that overexpression of Pin1 blocks mitotic entry by com-
promising phosphorylation of the upstream regulators of Cdc2.
These findings raise the possibility that p9 and Pin1 may
normally play antagonistic roles in controlling the G2/M tran-
sition. However, at this time, it is not known whether inhibi-
tion of mitotic entry by Pin1 could reflect a physiological func-
tion of Pin1 or is instead a consequence of its overexpression.
Further studies will be required to resolve conclusively the
physiological role of Pin1 in cell cycle control.
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FIG. 2. The Pin1 protein inhibits the p9-stimulated phospho-
rylation of substrates by Cdc2/Dcyclin B. A, His6-Cdc25 (top panel)
and His6-Myt1 (bottom panel) were incubated in kinase buffer contain-
ing [g-32P]ATP with no further addition (lane a), Cdc2/Dcyclin B (lanes
b and d), or p9/Cdc2/Dcyclin B (lanes c and e) in the absence (lanes a–c)
or presence of 100 mg/ml of His6-Pin1 (lanes d and e). B, dose-response
experiment for the inhibitory effect of His6-Pin1 on the phosphorylation
of His6-Cdc25. His6-Cdc25 was incubated in the presence of [g-32P]ATP
with Cdc2/Dcyclin B (lane a) or p9/Cdc2/Dcyclin B (lanes b–h) and
10–100 mg/ml His6-Pin1 as indicated (lanes c–h). C, His6-Pin1 does not
affect the histone H1 kinase activity of p9/Cdc2/Dcyclin B. Cdc2/Dcyclin
B (lane a) and p9/Cdc2/Dcyclin B (lanes b–d) were incubated in the
presence of [g-32P]ATP and histone H1 (0.1 mg/ml) either without
His6-Pin1 (lanes a and b) or with either 10 mg/ml His6-Pin1 (lane c) or
100 mg/ml His6-Pin1 (lane d). The concentrations of His6-Cdc25, His6-
Myt1, Cdc2/Dcyclin B, and p9/Cdc2/Dcyclin B were the same as in Fig.
1. All experiments were performed a minimum of three times.
FIG. 3. The inhibitory effect of His6-Pin1 on the phosphoryla-
tion of His6-Cdc25 by p9/Cdc2/Dcyclin B is mediated by the WW
domain of Pin1. His6-Cdc25 was incubated with Cdc2/Dcyclin B or
p9/Cdc2/Dcyclin B as described in Figs. 1 and 2 except that 25–125
mg/ml either wild-type His6-Pin1 or the mutant His6-Pin1-W34A was
included as indicated. All experiments were performed a minimum of
three times.
FIG. 4. Model summarizing the roles of p9 and Pin1 in the
mitotic phosphorylation of the Cdc25, Myt1, and Wee1 proteins.
(Note that the exact number of phosphate groups on Cdc25, Myt1, and
Wee1 at interphase and mitosis is not known.)
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